CHAMBER HILL STRATEGIES

Lobbying for OS THERAPIES · biotechnology company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · New York · House · Senate · posted Oct 17, 2025

Lobbying activity 2

Pharmacy

cancer immunotherapy and antibody treatment; osteosarcoma

Health Issues

cancer immunotherapy and antibody treatment; osteosarcoma

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.